Patients with liver cancer who received immune checkpoint inhibitors (ICIs) before surgery – including those who would not have been eligible for...
Vous n'êtes pas connecté
Physician scientists from City of Hope in the United States, found that people with metastatic kidney cancer who orally took a live biotherapeutic product called CBM588 while in treatment with immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes. The phase 1 trial was published today in Nature Medicine. Microorganisms in the gut modulate the immune system. City [...]
Patients with liver cancer who received immune checkpoint inhibitors (ICIs) before surgery – including those who would not have been eligible for...
Study finds that combining caloric restriction with psychological interventions significantly alters the gut microbiome and improves stress-related...
A study conducted in British Columbia seeks to understand how night work may affect the health of the gut microbiome, which may lead to an increased...
Deaths from advanced lung cancer have significantly declined since immunotherapy became standard-of-care, marking a major advancement in treatment...
In the past two decades, immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment, showing promising results against various solid...
Gene activity in the spleen tyrosine kinases pathway can predict severe side effects in melanoma patients undergoing immunotherapy.
An activity pattern in certain genes responsible for building proteins known as spleen tyrosine kinases can predict which melanoma patients are likely...
FRIDAY, Aug. 16, 2024 -- For patients with hepatocellular carcinoma (HCC), immune checkpoint inhibitor (ICI) use prior to liver transplant (LT) does...
Early exposure to common chemicals can cause permanent changes to the gut microbiome, potentially leading to long-term health impacts.
Progenitor exhausted CD8+ T (Tpex) cells have emerged as a pivotal component in tumour immunotherapy due to their unique ability to self-renew and...